Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer

Myrna Hurtado, Umesh Tanaji Sankpal, Amalendu Prakash Ranjan, Rajasekhar Maram, Jamboor K. Vishwanatha, Ganji Purnachandra Nagaraju, Bassel F. El-Rayes, Riyaz Mahammad Basha

Research output: Contribution to journalReview articleResearchpeer-review

3 Citations (Scopus)

Abstract

Pancreatic cancer (PC) continues to be a fatal malignancy. With standard treatments having modest impact, alternative courses of actions are being investigated such as enhancing the efficacy of standard treatment through sensitization of PC cells to chemotherapy or radiation. This review emphasizes investigational agents that increase the responses to chemotherapy or radiation in PC models. Our group has extensively investigated on Curcumin (Cur), analogs (EF31, UBS109, and L49H37), nanoparticles and a small molecule Tolfenamic acid (TA) for enhancing therapeutic efficacy in both in vitro and in vivo assays. Cur has a low level of toxicity and promising anti-cancer activity, however, its clinical development has been limited by low bioavailability. Cur analogs and nanoparticles were synthesized to improve Cur's efficacy and bioavailability. These compounds were found to be effective in enhancing the therapeutic effects of chemotherapy in pre-clinical models. Small molecules such as NSAIDs have also been tested for the anti-cancer activity and induction of response of chemotherapy and radiation. Interest in TA, a NSAID, has recently increased due to promising preclinical data demonstrating its anti-cancer properties with minimum toxicity. TA also synergistically increased the response of XRT in PC cells and in an orthotropic mouse model. With strong preclinical evidence, research aimed at developing less toxic therapies for PC using Cur analogues or TA is ready for translation into clinical testing.

Original languageEnglish
Pages (from-to)201-207
Number of pages7
JournalCritical Reviews in Oncology/Hematology
Volume126
DOIs
StatePublished - 1 Jun 2018

Fingerprint

Pancreatic Neoplasms
Curcumin
Radiation
Drug Therapy
Non-Steroidal Anti-Inflammatory Agents
Nanoparticles
Biological Availability
Neoplasms
Induction Chemotherapy
Poisons
Therapeutic Uses
Therapeutics
tolfenamic acid
Research

Keywords

  • Chemotherapy
  • Combination treatment
  • Pancreatic cancer
  • Radiation

Cite this

@article{827f38f9edf14b828826fd6b87869e3e,
title = "Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer",
abstract = "Pancreatic cancer (PC) continues to be a fatal malignancy. With standard treatments having modest impact, alternative courses of actions are being investigated such as enhancing the efficacy of standard treatment through sensitization of PC cells to chemotherapy or radiation. This review emphasizes investigational agents that increase the responses to chemotherapy or radiation in PC models. Our group has extensively investigated on Curcumin (Cur), analogs (EF31, UBS109, and L49H37), nanoparticles and a small molecule Tolfenamic acid (TA) for enhancing therapeutic efficacy in both in vitro and in vivo assays. Cur has a low level of toxicity and promising anti-cancer activity, however, its clinical development has been limited by low bioavailability. Cur analogs and nanoparticles were synthesized to improve Cur's efficacy and bioavailability. These compounds were found to be effective in enhancing the therapeutic effects of chemotherapy in pre-clinical models. Small molecules such as NSAIDs have also been tested for the anti-cancer activity and induction of response of chemotherapy and radiation. Interest in TA, a NSAID, has recently increased due to promising preclinical data demonstrating its anti-cancer properties with minimum toxicity. TA also synergistically increased the response of XRT in PC cells and in an orthotropic mouse model. With strong preclinical evidence, research aimed at developing less toxic therapies for PC using Cur analogues or TA is ready for translation into clinical testing.",
keywords = "Chemotherapy, Combination treatment, Pancreatic cancer, Radiation",
author = "Myrna Hurtado and Sankpal, {Umesh Tanaji} and Ranjan, {Amalendu Prakash} and Rajasekhar Maram and Vishwanatha, {Jamboor K.} and Nagaraju, {Ganji Purnachandra} and El-Rayes, {Bassel F.} and Basha, {Riyaz Mahammad}",
year = "2018",
month = "6",
day = "1",
doi = "10.1016/j.critrevonc.2018.03.016",
language = "English",
volume = "126",
pages = "201--207",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer. / Hurtado, Myrna; Sankpal, Umesh Tanaji; Ranjan, Amalendu Prakash; Maram, Rajasekhar; Vishwanatha, Jamboor K.; Nagaraju, Ganji Purnachandra; El-Rayes, Bassel F.; Basha, Riyaz Mahammad.

In: Critical Reviews in Oncology/Hematology, Vol. 126, 01.06.2018, p. 201-207.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer

AU - Hurtado, Myrna

AU - Sankpal, Umesh Tanaji

AU - Ranjan, Amalendu Prakash

AU - Maram, Rajasekhar

AU - Vishwanatha, Jamboor K.

AU - Nagaraju, Ganji Purnachandra

AU - El-Rayes, Bassel F.

AU - Basha, Riyaz Mahammad

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Pancreatic cancer (PC) continues to be a fatal malignancy. With standard treatments having modest impact, alternative courses of actions are being investigated such as enhancing the efficacy of standard treatment through sensitization of PC cells to chemotherapy or radiation. This review emphasizes investigational agents that increase the responses to chemotherapy or radiation in PC models. Our group has extensively investigated on Curcumin (Cur), analogs (EF31, UBS109, and L49H37), nanoparticles and a small molecule Tolfenamic acid (TA) for enhancing therapeutic efficacy in both in vitro and in vivo assays. Cur has a low level of toxicity and promising anti-cancer activity, however, its clinical development has been limited by low bioavailability. Cur analogs and nanoparticles were synthesized to improve Cur's efficacy and bioavailability. These compounds were found to be effective in enhancing the therapeutic effects of chemotherapy in pre-clinical models. Small molecules such as NSAIDs have also been tested for the anti-cancer activity and induction of response of chemotherapy and radiation. Interest in TA, a NSAID, has recently increased due to promising preclinical data demonstrating its anti-cancer properties with minimum toxicity. TA also synergistically increased the response of XRT in PC cells and in an orthotropic mouse model. With strong preclinical evidence, research aimed at developing less toxic therapies for PC using Cur analogues or TA is ready for translation into clinical testing.

AB - Pancreatic cancer (PC) continues to be a fatal malignancy. With standard treatments having modest impact, alternative courses of actions are being investigated such as enhancing the efficacy of standard treatment through sensitization of PC cells to chemotherapy or radiation. This review emphasizes investigational agents that increase the responses to chemotherapy or radiation in PC models. Our group has extensively investigated on Curcumin (Cur), analogs (EF31, UBS109, and L49H37), nanoparticles and a small molecule Tolfenamic acid (TA) for enhancing therapeutic efficacy in both in vitro and in vivo assays. Cur has a low level of toxicity and promising anti-cancer activity, however, its clinical development has been limited by low bioavailability. Cur analogs and nanoparticles were synthesized to improve Cur's efficacy and bioavailability. These compounds were found to be effective in enhancing the therapeutic effects of chemotherapy in pre-clinical models. Small molecules such as NSAIDs have also been tested for the anti-cancer activity and induction of response of chemotherapy and radiation. Interest in TA, a NSAID, has recently increased due to promising preclinical data demonstrating its anti-cancer properties with minimum toxicity. TA also synergistically increased the response of XRT in PC cells and in an orthotropic mouse model. With strong preclinical evidence, research aimed at developing less toxic therapies for PC using Cur analogues or TA is ready for translation into clinical testing.

KW - Chemotherapy

KW - Combination treatment

KW - Pancreatic cancer

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=85046131662&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2018.03.016

DO - 10.1016/j.critrevonc.2018.03.016

M3 - Review article

VL - 126

SP - 201

EP - 207

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -